Suramin for the Treatment of Autism Trial (STAT): A Randomized, Double Blind, Crossover Trial of KZ101 in a Male Pediatric Population With Autism Spectrum Disorder

Suramin has been found to correct the symptoms, metabolism, and brain synaptic abnormalities in two classical genetic and environmental mouse models of autism. A preliminary clinical trial (SAT-1) examined the safety and activity of a single low-dose of suramin in children with ASD and concluded suramin showed promise as a novel approach to treatment of ASD. The current study, STAT-2A, will be a randomized, double-blind, crossover, 30-week study to evaluate the preliminary proof of concept, safety, and PK of suramin sodium (KZ101) with repeat dosing by IV infusion in males 5-14 years of age who have been diagnosed with ASD. The study will be conducted at approximately 3 sites contributing approximately 15 subjects per site. Total enrollment of approximately 45 subjects is planned to achieve approximately 36 participants completing the study.

Start Date01 Apr 2025

Sponsor / Collaborator

Children's Hospital of Orange County

[+1]

NCT06772662

/ RecruitingNot Applicable

One Up, One Down: Analyzing Patient Preference on Cryotherapy Machine Tubing Placement

The purpose of this research study is to better understand patient preference and their satisfaction rates with cryotherapy machines based on the direction of the tubing. This study will evaluate both satisfaction and pain of patients who use the cryotherapy machines in the two groups: tubing facing towards the head, and the other with tubing facing toward the feet.

Start Date08 Jan 2025

Sponsor / Collaborator

Children's Hospital of Orange County

NCT06608966

/ RecruitingNot ApplicableIIT

Epilepsy Journey 2.0: An Intervention to Improve Executive Functioning in Adolescents With Epilepsy

The goal of this multi-site clinical trial is to determine the effectiveness of two components of a web-based intervention (Epilepsy Journey) to improve executive functioning in adolescents with epilepsy. The two components include web-based modules and problem-solving telehealth sessions with a therapist focused on executive functioning. This trial aims to answer the following questions:
1. Which components of Epilepsy Journey (web-based modules or telehealth sessions with a therapist) are essential for improving executive functioning in adolescents with epilepsy?
2. Which components of Epilepsy Journey (web-based modules or telehealth sessions with a therapist) are essential for improving quality of life in adolescents with epilepsy?
Participants will be randomly assigned to one of four groups: 1) Epilepsy Journey web-based modules and telehealth sessions, 2) Epilepsy Journey web-based modules only, 3) telehealth sessions with a therapist only, or 4) treatment as usual.
Participants will:
* Independently review Epilepsy Journey web-based modules focused on executive functioning skills (
15-30 minutes) and/or have weekly telehealth sessions (
30-45 minutes) with a therapist for 14 weeks.
* Complete measures of executive functioning (parent and teen-report) and quality of life (teen-report) at the start of the study, 14-, 26-, and 66- weeks after randomization. The NIH toolbox will be completed at the start of the study and 26-weeks after randomization. Additional measures will also be collected.

Start Date11 Nov 2024

Sponsor / Collaborator

Children's Hospital & Medical Center

[+5]

100 Clinical Results associated with Children's Hospital of Orange County

0 Patents (Medical) associated with Children's Hospital of Orange County

1,268

Literatures (Medical) associated with Children's Hospital of Orange County

01 Jul 2025·BRAIN BEHAVIOR AND IMMUNITY

Differential immune profiles in the context of chronic stress among childhood adversity-exposed adolescents

Article

Author: Cole, Steve W ; Tan, Ece N ; Kuhlman, Kate Ryan ; Rao, Uma

Psychosocial stress has been linked to myriad mental and physical health conditions. Stress-induced changes to functioning of the immune system is a plausible mechanism in this association. Psychosocial stress is a well-established contributor to immune dysregulation, though the extant literature to date falls short of addressing the role of distal relative to contemporary stress in immune function, particularly as they relate to distinctions between innate and adaptive immunity. The present study directly addressed this knowledge gap by characterizing vertically-integrated markers of immune functioning as a function of both recent chronic stress during adolescence and childhood adversity. In the present study, childhood adversity (before age 10) and recent psychosocial stressors (past 6 months) were characterized via semi-structured clinical interviews among 127 adolescent girls (aged 13-17; 31 % Black, 38 % Hispanic, 32 % NHW) who have all measures included in this report. Vertically-integrated markers of immune activity were also collected: an a priori subset of immune-related genes using genome-wide transcriptional profiling, an 11-plex of circulating cytokines (IL-6, TNF-α, IL-10, IL-8, IFN-γ, IL-1β, IL-1α, IL-27, MCP-1, IL-12p70, IP-10), and systemic inflammation (C-reactive protein; CRP). The association between recent chronic stress and intracellular immune outcomes differed based on childhood adversity. Genome-wide transcriptional profiling implicated myeloid lineage cells, specifically monocytes and dendritic cells, in differential patterns of gene expression among childhood adversity-exposed youth in the context of chronic stress. These differential patterns were also reflected in expression of proinflammatory genes and CRP such that among adolescents without exposure to childhood adversity, more recent chronic stress was associated with less proinflammatory gene expression, b = -0.45 (SE = 0.22), p = 0.04, 95 %CI [-0.87, -0.02], and somewhat higher CRP, b = 0.62 (SE = 0.35), p = 0.08, 95 %CI [-0.07, 1.31], while among adolescents with exposure to childhood adversity, more recent chronic stress was not associated with any immune activity markers. However, these patterns among circulating markers did not survive corrections for multiple comparisons. Immune adaptation in the context of chronic stress may indicate plasticity to environmental demands that conserves biological resources, which may be a source of resilience that is negatively impacted by childhood adversity.

01 Apr 2025·AMERICAN JOURNAL OF PERINATOLOGY

Cost Comparison of a Traditional Didactic versus National Flipped Classroom Curriculum

Article

Author: Falck, Alison J. ; Johnston, Lindsay C. ; Dadiz, Rita ; Gillam-Krakauer, Maria ; Vasquez, Margarita M. ; Izatt, Susan ; Chess, Patricia R. ; French, Heather M. ; Gisondo, Carly ; Karpen, Heidi ; Gray, Megan M. ; Payne, Allison ; Bonachea, Elizabeth M. ; Carbajal, Melissa M. ; Arias-Shah, AnnaMarie

Abstract:

We compared the cost of faculty time preparing educational materials for traditional didactic (TD) education provided at local institutions with that of faculty time preparing National Neonatology Curriculum (NNC) flipped classroom (FC) educational materials shared among institutions for fellow education across the United States.Using survey data and the national average for faculty educators' salaries, we calculated the cost of developing TD versus FC materials. Wilcoxon rank-sum test and comparison of two Poisson rates were utilized to evaluate the time to create versus update TD materials and the cost to create new TD versus FC materials, respectively.FC materials required more time to develop than TD materials (FC, median 17 h, interquartile range [IQR]: 17; TD, median, 5 h, IQR: 5; p < 0.001). However, when the size of individual fellowship programs was factored into the cost analysis, FC materials shared nationally among programs resulted in a 19- to 72-fold cost savings when compared to the creation of new locally used TD materials (FC, $2.49 per fellow; TD $32.05–576.90 per fellow at very large-to-small fellowship programs; p < 0.001).Educational materials developed and disseminated to fellowship programs across the country confer significant savings in faculty educator time and cost per learner. Standardized programs such as the NNC may serve as a model to develop shared peer-reviewed educational resources for other specialties.

01 Apr 2025·ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY

Use of Social Media to Source Medical Information Among Parents of Pediatric Otolaryngology Clinic Patients: A Survey Study

Article

Author: Bhatt, Jay ; Sharma, Arjun ; Goshtasbi, Khodayar

Objective::

The reach and impact of social media as it pertains to medical information among the parents and guardians of pediatric otolaryngology patients is unknown. This survey-based study investigates the use of social media as a source of medical knowledge in this population.

Methods::

Parents and guardians visiting a pediatric Otolaryngology clinic located at a tertiary care children’s hospital in southern California from September 2022 to May 2023 were approached for study inclusion. Decision tree and logistic regression analysis was conducted to identify patterns of social media usage in association with factors of interest.

Results::

Of the 400 parents included in the study, most were female (80.0%); 49.5% were 30 to 40 years of age, and 18.8% were <30 years old. Most (90.0%) used social media, and 44.5% actively used it to obtain health information related to care for their children. A large proportion of parents (73.0%) were interested in social media content to better understand their child’s condition, particularly the opportunity to view videos and images of a surgery planned for their child (75.0%). About half (50.5%) would permit their child’s doctor to post about their child on social media, and 53.8% stated they would be more inclined to choose a surgeon who uses social media to educate families about their child’s condition.

Conclusion::

Most parents/guardians were interested in and had obtained critical medical information on social media, especially content pertaining to their child’s medical condition(s). Analysis of survey responses identified the social media content most valued by parents/guardians of children undergoing otolaryngological surgery. These findings can be used by pediatric otolaryngologists to better understand their patients’ preferences and improve access to health information for their patients on social media, as well as to grow their practices.

News (Medical) associated with Children's Hospital of Orange County

03 Mar 2025

·www.prnewswire.com

CureDuchenne and Children's Hospital of Orange County Partner to Bring World-Class Care to Families with Duchenne Muscular Dystrophy

CureDuchenne Clinic within the Neuromuscular Program at CHOC Will Expand Access to Exceptional Care, Deliver Cutting-Edge Treatments, and Drive Innovative Research NEWPORT BEACH, Calif., March 3, 2025 /PRNewswire/ -- CureDuchenne, a global leader in Duchenne muscular dystrophy (DMD) research, care, and advocacy, has announced a landmark partnership with Children's Hospital of Orange County (CHOC) to establish the CureDuchenne Clinic within the Neuromuscular Program at CHOC. This initiative will provide state-of-the-art, multidisciplinary care and the latest advancements in diagnostics and treatment—all in one location, enhancing access to families in Southern California and beyond. CureDuchenne, a nonprofit based in Newport Beach, CA, that serves a global patient population, and CHOC, a premier pediatric healthcare system that is now part of Rady Children's Health, are building on decades of expertise to establish world-class care and research, integrating cutting-edge therapies, clinical trials, and expert-led services to enhance both quality of life and long-term outcomes for individuals with DMD and other neuromuscular diseases. CureDuchenne has granted CHOC nearly $1.5 million over three years to fund the CureDuchenne Clinic within the Neuromuscular Program at CHOC. Key aims of the partnership are to: expand CHOC's multidisciplinary neuromuscular program, offering a range of specialties all under one roof; advance the use of next-generation diagnostics for earlier and more precise disease monitoring. accelerate access to gene therapies and emerging treatments through the Outpatient Infusion Center to be located in CHOC's new nine-story, outpatient tower in Orange, CA; develop a national model for adult transition, ensuring long-term, comprehensive care as patients age; expand participation in clinical trials and research initiatives to ensure more individuals have access to promising therapies and scientific advancements; and create standards of care with a unique perspective on Southern California's diverse patient population, including prioritizing the special concerns of low-income families facing health inequities. "Comprehensive care from an experienced, multidisciplinary healthcare team is critical to addressing the complex needs of children living with Duchenne. Through our partnership with CHOC, we are creating a seamless, patient-centered approach that integrates expert clinical care with groundbreaking research and innovative treatments. With CHOC's world-class medical expertise and CureDuchenne's commitment to accelerating therapy development, the CureDuchenne Clinic at CHOC will not only enhance access to the best possible care but also drive forward the next generation of Duchenne treatments—helping individuals live longer, stronger lives," said Debra Miller, Founder and CEO of CureDuchenne. "I am so honored to provide leading-edge care for this special patient population and their families. Our Neuromuscular Program is deeply grateful to CureDuchenne for investing in our work to rapidly elevate how we care for our patients with DMD. We are at an incredible moment to drive advancements in care and our partnership with CureDuchenne will help us chart a bright future," said Dr. Julian Thomas, Medical Director of the Neuromuscular Program at CHOC. The CureDuchenne Clinic within the Neuromuscular Program at CHOC will be led by a dedicated team of leading specialists under the direction of Dr. Julian Thomas and Dr. John Crawford, Medical Director, Neurology, CHOC and Co-Medical Director CHOC Neurosciences Institute. About CureDuchenne Over twenty years ago, CureDuchenne was created with one goal: to find and fund a cure for Duchenne muscular dystrophy, one of the most common and severe forms of muscular dystrophy. Today, CureDuchenne is recognized as a global leader in research, patient care, and innovation for improving and extending the lives of those with Duchenne. CureDuchenne's innovative venture philanthropy model has advanced transformative treatments for Duchenne muscular dystrophy, including 18 projects that advanced to human clinical trials and multiple projects to overcome the limitations of exon-skipping and gene therapy. In addition, CureDuchenne contributed early funding to the first FDA-approved Duchenne drug, pioneered the first and only Duchenne physical and occupational therapist certification program and created an innovative biobank and data registry, accelerating research toward a cure. For more information on how to help raise awareness and funds needed for research, please visit cureduchenne.org. SOURCE CureDuchenne WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Gene TherapyDrug Approval

15 Jan 2025

·www.businesswire.com

OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma

NEW YORK--( BUSINESS WIRE )--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced positive data from a Phase 2b clinical trial ( NCT04974008 ) of OST-HER2 (OST31-164) - the Company’s HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma. The data demonstrate statistically significant results in the primary endpoint of the study, 12-month event free survival (‘EFS’), where an event is defined as the recurrence of metastatic osteosarcoma, in OST-HER2-treated patients when compared with the leading published historical comparable control group. Further as of the most recent follow up, the data show a strong trend in favor of OST-HER2-treated patients in overall survival (‘OS’, remaining alive) at the 1-year and 2-year interim timepoints of the ongoing 3-year overall survival secondary endpoint. Notably, all patients who achieved the primary 12-month EFS endpoint remain alive. “We are extremely pleased with these results of our Phase 2b clinical trial because they show that OST-HER2-treated patients achieved the primary endpoint of 12-month EFS in a statistically significantly higher ratio than comparable historical controls, in addition to increasing the likelihood of 1-year and 2-year survival as compared with comparable historical controls,” commented Dr. Robert Petit, Chief Medical & Scientific Officer of OS Therapies. “The strong safety profile shown in this study also supports the use of OST-HER2 in this incredibly difficult-to-treat population that has no currently approved therapies.” “The achievement of the primary endpoint in the OST-HER2 phase 2b is a tremendous success that opens the possibility, for the first time, of meaningful therapy for patients suffering from osteosarcoma with lung metastases after resection. This is a leap forward in the development of OST-HER2 and we are pleased that our regulatory strategy is consistent with the FDA’s recent draft guidance update for accelerated approvals. With these positive data in hand, we are preparing to engage with U.S. FDA on an accelerated pathway for approval in this extremely challenging indication,” said Paul Romness, MHP, Chair & CEO of OS Therapies. “We do not expect to have to treat additional patients as part of this process with FDA.” Phase 2b Clinical Trial Data Enrollment Criteria: 12-39 years old Recurred, fully resected lung only metastatic (METS) Osteosarcoma 39 evaluable patients at 21 centers, single treatment arm 52 Weeks on Study: Dosed 16 times every 3 weeks for 48 weeks with 4-week follow-up final visit Primary Endpoint of 12-month EFS: 33% for OST-HER2 vs. 20% for historical control 1 (p = 0.0158) Interim Analysis of Ongoing Secondary Endpoint, OS: 1-year OS: 91% for OST-HER2 vs. 80% for historical control 2 (p = 0.0700) 2-year OS: 61% for OST-HER2 vs. 40% for historical control 2 (p = 0.0576) Post-Hoc Analyses 12-months EFS Subgroup Analysis in the OST-HER2 Treatment Group: Gender (Males vs Females), n = 39: Females (n=19) = 47% Males (n= 20) = 20% (p= 0.0604) Number of lung resections (1 Prior Resection vs. 2+ Prior Resections), n= 39: 1 Prior Resection (n= 28) = 25% 2+ Prior Resections (n= 11) = 55% (p = 0.1366) 12-month EFS Responders using a Non-Concurrent Control Group from the only existing US osteosarcoma database with patients qualified for disease-free status following a fully-resected lung-only metastasis of osteosarcoma origin: OST-HER2, n=39 12-month EFS Responders = 13/39 (33%) NCCG, n=9 12-month EFS Responders = 1/9 (11%) (p = 0.1848) Time to recurrence in patients who did not achieve 12-month EFS: OST-HER2, n=26 = 5.9 months NCCG, n=8 = 4.7 months (p = 0.1454) About OST-HER2 OST-HER2 is an innovative immunotherapy using a HER2 bioengineered form of the bacteria Listeria monocytogenes (Lm) to trigger a strong immune response against cancer cells expressing HER2. This off-the-shelf immunotherapy treatment is designed to prevent metastasis, delay recurrence, kill primary tumors expressing HER2 alone and potentially in combination with existing approved therapies, and increase overall survival. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the FDA and Fast Track and Orphan Drug Designations from the FDA and European Medicines Agency (EMA). The US FDA granted OST-HER2 rare pediatric disease designation for osteosarcoma in 2021. The US FDA rare pediatric disease PRV program aims to incentivize drug development for rare pediatric diseases. Under this voucher program, a sponsor who receives an approval for a drug or biological product for a rare pediatric disease qualifies for a voucher that can be redeemed to receive priority review for a different product. The sponsor may also transfer or sell the voucher to another sponsor. OS Therapies intends to sell the PRV it would earn upon receiving an approval of OST-HER2 for recurrent, fully resected, lung metastatic osteosarcoma. The most recent publicly disclosed sale price of a PRV was on November 27 th , 2024 when PTC Therapeutics announced selling its PRV to Kebilidi for $150M. With emerging scarcity in the PRV market, the Company expects the value of PRVs to increase going forward. The maximum sale price of a PRV was in 2015 when AbbVie bought a priority review voucher from United Therapeutics for $350 million. The most recent continuing resolution (CR) negotiations in the US House of Representatives failed to reauthorize the PRV program for pediatric cancers such as osteosarcoma. Despite this, as a result of OS Therapies’ having been granted OST-HER2’s rare pediatric disease designation prior to December 20, 2024 in addition to the Company’s aim to receive an approval for OST-HER2 in the rare pediatric disease osteosarcoma in 2025, prior to the September 30, 2026 deadline, OS Therapies remains eligible to receive the PRV upon approval of OST-HER2 in recurrent, resected metastatic osteosarcoma. The osteosarcoma treatment market was estimated at $1.2 billion in 2022 according to Data Bridge Market Research . Approximately 50% of patients are diagnosed with a lung metastasis at some point following surgical resection and chemotherapy. 3-year survival rates in patients who were not diagnosed with a metastasis are 59% . 3-year survival rates in patients who were diagnosed with pulmonary metastasis were 30% . The Company believes the market opportunity for OST-HER2 in the prevention of lung metastases is over $500 million. About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com . Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and grant of a priority review voucher and other risks and uncertainties described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2024, as amended on November 27, 2024, and other subsequent documents we file with the SEC, including but not limited to our Quarterly Reports on Form 10-Q. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. 1 Lagmay JP, Krailo MD, Dang H, et al: Outcome of patients with recurrent osteosarcoma enrolled in seven Phase II trials through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: learning from the past to move forward. J Clin Oncol. 2016;34:3031-8 2 A.H. Aljubran, A. Griffin, M. Pintilie, M. Blackstein; Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases; Annals of Oncology; Volume 20, Issue 6; 2009;1136-41

Phase 2ImmunotherapyClinical ResultFast TrackOrphan Drug

19 Aug 2024

·www.prnewswire.com

University Lab Partners Announces the Winners of Orange County's 2024 Pitch. Launch. Grow. Competition

IRVINE, Calif., Aug. 19, 2024 /PRNewswire/ -- University Lab Partners (ULP) is proud to announce the winners of the 4th annual Pitch. Launch. Grow. competition, a hallmark event that continues to spotlight innovation in life sciences, medical technology, and pediatrics. This year's competition attracted over 40 applications, with startups competing for recognition across three specialized tracks. Continue Reading The winners in the Life Science and Medical Technology tracks each receive a one-year sponsored lab bench at University Lab Partners, the premier wet lab incubator in Irvine, California. The Pediatric track winner will not only receive the lab bench sponsorship but also a $2,500 prize from the Consortium for Technology & Innovation in Pediatrics (CTIP)—an FDA-funded pediatric device accelerator—and a one-hour virtual mentorship session with Dr. Terence Sanger, MD, PhD, Chief Scientific Officer at CHOC Research. ULP's Pitch. Launch. Grow. competition spotlights innovation in life sciences, medical technology, and pediatrics. Post this Dr. Sanger commended all participants, stating, "We extend our heartfelt gratitude to every founder in the Pediatric Device track. Your dedication and innovative spirit are exactly what the Pitch. Launch. Grow. competition aims to foster." Pitch. Launch. Grow. 2024 Winners: Life Science - Hybrid Biotherapeutics Inc. & Cellecho Biotech Medical Technology - Syntr Health Technologies, Inc. & iPill Dispenser Pediatric - Remmie Health ULP's life science startups are provided with unparalleled access to professional mentoring, consulting with Experts-in-Residence, networking events, and unique access to UCI's technical core facilities. Since its inception in 2019, ULP has incubated 64 companies that have collectively raised over $535 million, successfully graduating eight startups into the broader market. Konstantin Kazarian, CEO at Hybrid-Bio, shared, "As developers of a new solid tumor cell therapy, we're thrilled by the interest the competition brought us. This recognition means a lot to Hybrid Biotherapeutics, and we look forward to collaborating with ULP and utilizing their state-of-the-art laboratory facilities." The 2024 Pitch. Launch. Grow. winners were selected by a distinguished panel of judges, representing leading organizations including Johnson & Johnson, Wilson Sonsini Goodrich & Rosati, CHOC, General Inception, Woodgreen Ventures, Xinetix, and D2M Venture Development. Pitch. Launch. Grow. is made possible thanks to the generous sponsorship of Sunstone Management, Insperity, HATCHspaces, NexCore Group, and Wilson Sonsini Goodrich and Rosati. For more information, please visit About University Lab Partners: University Lab Partners (ULP) is a premier, nonprofit, wet lab incubator located in Orange County, CA. ULP operates 2 facilities in Irvine and Aliso Viejo, CA. ULP offers highly equipped wet lab facilities along with the benefits of accelerator services and peer-to-peer interactions among a life science-focused entrepreneurial community. SOURCE University Lab Partners

100 Deals associated with Children's Hospital of Orange County

100 Translational Medicine associated with Children's Hospital of Orange County

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 28 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

Approved

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Lidocaine/Adrenaline/Tetracaine ( RYR1 x RYR2 x SCNA x adrenergic receptor )	Lacerations More	Approved
rHSC-DIPGVax(Dana-Farber Cancer Institute) ( HSP )	Diffuse midline glioma, point mutation K27M in histone H3 More	Phase 1

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis